ArticleThe oncologist2026

Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis.

Abhiraj Saxena et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.